THE EMERGING ROLE OF MICRORNA-138 AS NOVEL DIAG- NOSTIC, PROGNOSTIC AND THERAPEUTIC TOOLS FOR BREAST CANCER
Abstract
Background and objectives: A multistep process called breast carcinogenesis is characterized by genetic and epigenetic changes. It is believed that miRNAs have a role in the onset and spread of breast cancer and also present attractive targets for such novel treatments. This study's goal was to investigate at the role of miR-138 in breast tumor invasion, metastasis, diagnosis, prognosis and treatment in Egyptian women, as well as their relevance to the molecular types of those processes. Methodology: A total of 150 individuals were included in the present study, including 75 breast cancer and 75 supposedly healthy women who were age and gender matched. All historical data mammogram, and laboratory tests were performed on each patient. These tests included the determination of miR-138 expression levels by real-time PCR, serum CEA and CA15-3 levels, and general clinical examination. Results: The expression level of miR-138 was considerably higher (P<0.001) in breast cancer patients than control group. In triple negative cases and instances of other types, low expression (13.48) miR-138 was reported with a significant difference with control group (p2=0.002*, p30.001*). A substantial inverse relationship between miR-138 and the levels of the tumor markers CEA and CA15.3. In patients with high expression miR-138 had substantially higher overall survival (P=0.049). Metastasis status, CA15.3.value, chemotoxicity, and miR-138 were all significant predictors for mortality and metastasis status, PT status (≥3), PN status (≥3), CEA value, CA15.3 and miR-138 were significant predictors of relapse. Conclusion: The miR-138 suppression may promote metastasis. Consequently, the restoration of miR-138 in breast cancer may have therapeutic potential, so the miR-138 may play a role in breast cancer development.
References
Bahari Khasraghi L., Nouri M., Vazirzadeh M., Hashemipour, N., Talebi M., and Aghaei Zarch F., (2023). 'MicroRNA-206 in human cancer: Mechanistic and clinical perspectives', Cell Signal, 101: 11025.
Bockhorn J., Prat A., Chang Y. F., Liu X., Huang S. and Shang M., (2014). 'Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient- derived breast cancer models', Cancer Res., 74: 7406-7417.
Ding J., Yeh C. R., Sun Y., Lin C., Chou J. and Ou Z., (2018). 'Estrogen receptor β promotes renal cell carcinoma progression via regulating LncRNA HOTAIR- miR-138/200c/204/217 associated CeRNA network', Oncogene, 37: 5037-5053.
Dvinge H., Git A., Gräf S., Salmon-Divon M., Curtis C. and Sottoriva A., (2013). 'The shaping and functional consequences of the microRNA landscape in breast cancer', Nature, 497: 378-382.
Francis S. V., Sasikala M., Bharathi G. B. and Jaipurkar S. D., (2014). 'Breast cancer detection in rotational thermography images using texture features', Infrared Phys. Technol., 67: 490-496.
Giaquinto A. N., Miller K. D., Tossas K. Y., Winn R. A., Jemal A. and Siegel R. L., (2022). 'Cancer statistics for African American/Black People 2022', CA Cancer J. Clin., 72: 202-2029.
Ibrahim A. S., Khaled H. M., Mikhail N. N., Baraka H. and Kamel H., (2014). 'Cancer incidence in egypt: results of the national population- based cancer registry program', J. Cancer Epidemiol, 2014: 437- 4371.
Klinge C. M. (2012). 'miRNAs and estrogen action', Trends Endocrinol Metab., 23: 223-233.
Kunc M., Popęda M., Niemira M., Szałkowska A., Bieńkowski M. and Pęksa R., (2020). 'microRNA expression profile in single hormone receptor-positive breast cancers is mainly dependent on HER2 status-a pilot study', Diagnostics (Basel), 10: 46-49.
Lehmann B. D., Bauer J. A., Chen X., Sanders M. E., Chakravarthy A. B. and Shyr Y., (2011). 'Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies', J. Clin. Invest., 121: 2750-2767.
Liang Z., Feng Q., Xu L., Li S. and Zhou L., (2017). 'CREPT regulated by miR-138 promotes breast cancer progression', Biochem Biophys Res. Commun., 493: 263-629.
Lowery A. J., Miller N., Devaney A., McNeil, R. E., Davoren P. A. and Lemetre C., (2009). 'MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer', Breast Cancer Res., 11: 27-29.
Mahmoudzadeh E., Montazeri M., Zekri M. and Sadri S., (2015). 'Extended hidden Markov model for optimized segmentation of breast thermography images', Infrared Phys Technol., 72: 19-28.
Miller K. D., Ortiz A. P., Pinheiro P. S., Bandi P., Minihan A. and Fuchs H. E., (2021). 'Cancer statistics for the US Hispanic/Latino population, 2021', CA Cancer J. Clin., 71: 466-487.
Nama S., Muhuri M., Di Pascale F., Quah S., Aswad L. and Fullwood M., (2019). 'MicroRNA-138 is a prognostic biomarker for triple- negative breast cancer and promotes tumorigenesis via TUSC2 repression', Sci. Rep., 9: 127-128.
Shirvani H., Ghanavi J., Aliabadi A., Mousavinasab F., Talebi M. and Majidpoor J., (2023). 'MiR-211 plays a dual role in cancer development: From tumor suppressor to tumor enhancer', Cell Signal, 101: 110-115.
Sung H., Ferlay J., Siegel R. L., Laversanne M., Soerjomataram and I., Jemal A., (2021). 'Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries', CA Cancer J. Clin., 71: 209-249.
Uygur M. M. and Gümüş M., (2021). 'The utility of serum tumor markers CEA and CA 15-3 for breast cancer prognosis and their association with clinicopathological parameters', Cancer Treat. Res. Commun., 28: 100402.
Volovat S. R., Volovat C., Hordila I., Hordila D. A., Mirestean C. C. and Miron O. T., (2020). 'MiRNA and LncRNA as potential biomarkers in triple-negative breast cancer: A review', Front Oncol, 10: 526-850.
Wang G., Dong Y., Liu H., Ji N., Cao J. and Liu A., (2022). 'Long noncoding RNA (lncRNA) metallothionein 1 J, pseudogene (MT1JP) is downregulated in triple-negative breast cancer and upregulates microRNA-138 (miR- 138) to downregulate hypoxia- inducible factor-1α (HIF-1α)', Bioengineered, 13: 13718-13727.
Wu H. J. and Chu P. Y., (2022). 'Current and developing liquid biopsy techniques for breast cancer', Cancers (Basel), 14: 22-35.
Yeh M., Oh C. S., Yoo J. Y., Kaur B. and Lee T. J., (2019). 'Pivotal role of microRNA-138 in human cancers', Am. J. Cancer Res., 9: 1118-1126.
Zhao C., Ling X., Li X., Hou X. and Zhao D., (2019). 'MicroRNA-138-5p inhibits cell migration, invasion and EMT in breast cancer by directly targeting RHBDD1', Breast cancer, 26: 817-825.
Zhao S., Mei Y., Wang J., Zhang K. and Ma R., (2016). 'Different Levels of CEA, CA153 and CA125 in Milk and Benign and Malignant Nipple Discharge', PLoS One, 11: 157- 169.
Zubor P., Kubatka P., Kajo K., Dankova Z., Polacek H. and Bielik T., (2019). 'Why the gold standard approach by mammography demands extension by multiomics? Application of liquid biopsy mirna profiles to breast cancer disease management', Int. J. Mol. Sci., 20: 44-49.
